Avatrombopag in the Treatment of Pediatric Immune Thrombocytopenia
A Prospective, One-arm and Open Clinical Study to Assess Efficacy and Safety of Avatrombopag in the Treatment of Pediatric Primary Immune Thrombocytopenia
Institute of Hematology & Blood Diseases Hospital, China
60 participants
Mar 1, 2024
INTERVENTIONAL
Conditions
Summary
To evaluate the safety and efficacy of avatrombopag in the treatment of pediatric primary immune thrombocytopenia in patients who have been treated with eltrombopag before and switched to avatrobopag because of poor efficacy, excessive platelet fluctuation or intolerance, or patient preference, economic reasons, and other reasons.
Eligibility
Inclusion Criteria5
- Age 6-18 years old (including both ends), male and female;
- Diagnosed with primary immune thrombocytopenia (ITP);
- Patients who had previously received eltrombopag treatment and then converted to avatrombopag treatment because of ineffectiveness (platelet count \< 30×10\^9/L after eltrombopag treatment, or platelet count increased less than 2 times of the basic value, or bleeding) or large platelet fluctuation or due to patient preference, economic reasons and other reasons;
- Cardiac function of the New York Society of Cardiac Function ≤ 2;
- Understand the study procedure and voluntarily sign the informed consent.
Exclusion Criteria7
- Secondary thrombocytopenia caused by various reasons, such as connective tissue disorders, bone marrow hematopoietic failure disease, myelodysplastic syndrome, malignancy, drugs, inherited thrombocytopenia, common variable immune deficiency, lymphoma, etc.;
- Subjects with primary disease of important organs (liver, kidney, heart, etc.), or with immune system diseases;
- Subjects who are known to be allergic to avatrombopag or any of its excipients;
- Subjects who had used rituximab within the last 3 months;
- Subjects who underwent splenectomy within the last 3 months；
- Subjects with a history of abnormal platelet aggregation that may affect the reliability of platelet count measurements；
- Any medical history or condition that the investigator deems unsuitable for participation in the study.
Interventions
After enrollment, all subjects receive Avatrombopag treatment. The initial dose of Avatrombopag administration was an oral 10 mg (\<30kg) or 20mg (≥30kg) once daily in all participants. ps. For subjects weighing ≥30kg, the dose can be started from 40mg once daily if the platelet count is \< 10×10\^9/L or if there is severe bleeding or risk of bleeding. Complete blood count including platelet count was done once a week. The dose of Avatrombopag was adjusted according to the subject platelet count during the period from week 1 to week 24. If the platelet count was less than 30×10\^9/L for 2 weeks, avatrobopag was gradually increased. If the platelet count was greater than 150 x 10\^9/L, avatrobopag was gradually reduced. If the platelet count \>250×10\^9/L, avatrobopag will be stoped until the platelet count \<100×10\^9/L.
Locations(1)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT06281327